Funding, News and Announcements

Myeloma Canada and Pfizer Canada are pleased to collaborate to offer a grant opportunity to support Quality Improvement (QI) projects that will advance the quality of care and best practices around treatment for patients with relapsed/refractory multiple myeloma (RRMM) receiving bispecific antibody (BsAb) treatment.

This RFP is being issued by both organizations. Myeloma Canada is the lead organization for review and evaluation of proposals. A review committee, led by Myeloma Canada, will make decisions on which proposals will receive funding.

Read more about this call here.

Deadlines

Internal: May 18, 2023 at 4:30pm. Contact email is ird@dal.ca. For additional resources, click here for guidance on internal deadlines and submission processes.

Funder: June 1, 2023. Contacts are Gabriele Colasurdo, gcolasurdo@myeloma.ca or Amanda Kaczerski, Amanda.Kaczerski@pfizer.com